Rapid Therapeutic Science Laboratories, Inc. (RTSL) Liabilities and Shareholders Equity (2016 - 2023)
Rapid Therapeutic Science Laboratories' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $2.1 million for Q2 2023.
- For Q2 2023, Liabilities and Shareholders Equity fell 14.64% year-over-year to $2.1 million; the TTM value through Jun 2023 reached $8.6 million, down 7.49%, while the annual FY2022 figure was $2.3 million, 2.48% up from the prior year.
- Liabilities and Shareholders Equity for Q2 2023 was $2.1 million at Rapid Therapeutic Science Laboratories, up from $2.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.7 million in Q1 2022 and bottomed at $1334.0 in Q1 2019.
- The 5-year median for Liabilities and Shareholders Equity is $1.3 million (2020), against an average of $1.3 million.
- The largest annual shift saw Liabilities and Shareholders Equity plummeted 94.92% in 2019 before it skyrocketed 33227.44% in 2020.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $452632.0 in 2019, then surged by 234.25% to $1.5 million in 2020, then soared by 45.41% to $2.2 million in 2021, then increased by 2.48% to $2.3 million in 2022, then dropped by 7.99% to $2.1 million in 2023.
- Per Business Quant, the three most recent readings for RTSL's Liabilities and Shareholders Equity are $2.1 million (Q2 2023), $2.0 million (Q1 2023), and $2.3 million (Q4 2022).